 |
|
Cost-effectiveness of the Lower Treatment Goal (of JNC VI) for Diabetic Hypertensive Patients
William J. Elliott, MD, PhD;
David R. Weir, PhD;
Henry R. Black, MD
Arch Intern Med. 2000;160:1277-1283.
Background The recommendation of the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) to lower blood pressure (BP) in diabetic patients to less than 130/85 mm Hg may have negative economic consequences. A formal cost-effectiveness analysis was therefore performed, comparing the costs and potential benefits of a BP goal of less than 140/90 mm Hg (as recommended by JNC V) vs less than 130/85 mm Hg (as in JNC VI).
Methods A 24-cell computer model was populated with costs (1996 dollars), relative risks, and age-specific baseline rates for death and 4 nonfatal adverse events (stroke, myocardial infarction, heart failure, and end-stage renal disease), derived from published data. Costs and benefits were discounted at 3%.
Results For 60-year-old diabetic persons with hypertension, treating to the lower BP goal increases life expectancy by 0.48 (discounted) years and lowers (discounted) lifetime medical costs by $1450 compared with treating BP to less than 140/90 mm Hg. The lower treatment BP goal results in an overall cost savings over a wide range of initial conditions, and for nearly all analyses for patients older than 60 years.
Conclusions Any incremental treatment for 60-year-olds that costs less than $414 annually and successfully lowers BP from below 140/90 to below 130/85 mm Hg would be cost saving in the long term, due to the reduction in attendant costs of future morbidity. The lower treatment goal recommended for high-risk hypertensive patients compares favorably in cost-effectiveness with many other frequently recommended treatment strategies, and saves money overall for patients aged 60 years and older.
From the Department of Preventive Medicine, Rush Medical College of Rush University at Rush-Presbyterian-St Luke's Medical Center (Drs Elliott and Black), and the Irving B. Harris Graduate School of Public Policy Studies and the Department of Economics, The University of Chicago (Dr Weir), Chicago, Ill.
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(9):1379-1380.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The cost of glucocorticoid-associated adverse events in rheumatoid arthritis
Pisu et al.
Rheumatology (Oxford) 2005;44:781-788.
ABSTRACT
| FULL TEXT
Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis
Hoerger et al.
ANN INTERN MED 2004;140:689-699.
ABSTRACT
| FULL TEXT
Guidelines for Hypertension: Are Quality-Assurance Measures on Target?
Singer et al.
Hypertension 2004;43:198-202.
ABSTRACT
| FULL TEXT
Task Force #2--the cost of prevention: can we afford it? Can we afford not to do it?
Krumholz et al.
J Am Coll Cardiol 2002;40:603-615.
FULL TEXT
Optimizing the diabetic formulary: beyond aspirin and insulin
Marso
J Am Coll Cardiol 2002;40:652-661.
ABSTRACT
| FULL TEXT
Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: Rationale and Design
Shea et al.
J. Am. Med. Inform. Assoc. 2002;9:49-62.
ABSTRACT
| FULL TEXT
The Treatment of Hypertension in Adult Patients With Diabetes
Arauz-Pacheco et al.
Diabetes Care 2002;25:134-147.
FULL TEXT
|
